Search

Your search keyword '"Yasojima H"' showing total 11 results
Start Over Author "Yasojima H" Search Limiters Peer Reviewed
11 results on '"Yasojima H"'

1. GEOFENCING-BASED LOCALIZATION FOR 3D DATA ACQUISITION NAVIGATION.

Author

Nakagawa, M., Kamio, T., Yasojima, H., and Kobayashi, T.

Subjects
AUTONOMOUS robots, INDOOR positioning systems, MOBILE geographic information systems
Abstract

Users require navigation for many location-based applications using moving sensors, such as autonomous robot control, mapping route navigation and mobile infrastructure inspection. In indoor environments, indoor positioning systems using GNSSs can provide seamless indoor-outdoor positioning and navigation services. However, instabilities in sensor position data acquisition remain, because the indoor environment is more complex than the outdoor environment. On the other hand, simultaneous localization and mapping processing is better than indoor positioning for measurement accuracy and sensor cost. However, it is not easy to estimate position data from a single viewpoint directly. Based on these technical issues, we focus on geofencing techniques to improve position data acquisition. In this research, we propose a methodology to estimate more stable position or location data using unstable position data based on geofencing in indoor environments. We verify our methodology through experiments in indoor environments. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

5. 411P Interim analysis of prospective observational study to evaluate the impact of cancer gene panel tests on treatment decision making in metastatic or recurrent breast cancer in Japan: JBCRG-C07 REIWA study.

Author

Masuda, H., Hattori, M., Tada, H., Sagara, Y., Adachi, Y., Iwatani, T., Uemoto, Y., Otani, Y., Kajiwara, Y., Kitagawa, D., Kogawa, T., Shien, T., Tanabe, Y., Tanioka, M., Hara, F., Yasojima, H., Yoshimura, K., Iwata, H., and Masuda, N.

Subjects
*CANCER genes, *DECISION making, *LONGITUDINAL method, *SCIENTIFIC observation
Published
2024
Full Text
View/download PDF

6. 359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study

Author

Nakayama, T., Nagai, S.E., Hattori, M., Yoshinami, T., Masuda, H., Okamura, T., Watanabe, K-I., Tsuneizumi, M., Takabatake, D., Harao, M., Yasojima, H., Oshiro, C., Iwase, M., Yamaguchi, M., Sangai, T., Sasada, S., Ishida, T., Futamura, M., Kosaka, N., and Masuda, N.

Subjects
*EPIDERMAL growth factor receptors, *METASTATIC breast cancer, *HORMONE therapy, *JAPANESE people, *OVERALL survival
Published
2024
Full Text
View/download PDF

7. 4 Oral - Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study.

Author

Cardoso, F., O'Shaughnessy, J., McArthur, H., Schmid, P., Cortes, J., Harbeck, N., Telli, M.L., Cescon, D.W., Fasching, P., Shao, Z., Loirat, D., Park, Y.H., Gonzalez Fernandez, M., Rubovszky, G., Im, S.A., Hui, R., Takano, T., André, F., Yasojima, H., and Liu, Z.

Subjects
*BREAST tumor risk factors, *BREAST tumors, *TREATMENT effectiveness, *CONFERENCES & conventions, *MONOCLONAL antibodies, *ADJUVANT chemotherapy, *COMBINED modality therapy, *HORMONE therapy, *EVALUATION
Published
2024
Full Text
View/download PDF

8. LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer.

Author

Cardoso, F., McArthur, H.L., Schmid, P., Cortés, J., Harbeck, N., Telli, M.L., Cescon, D.W., O'Shaughnessy, J., Fasching, P., Shao, Z., Loirat, D., Park, Y.H., González Fernández, M.E., Liu, Z., Yasojima, H., Ding, Y., Jia, L., Karantza, V.V., Tryfonidis, K.E., and Bardia, A.

Subjects
*HORMONE therapy, *BREAST cancer, *PLACEBOS, *PEMBROLIZUMAB, *CANCER chemotherapy
Published
2023
Full Text
View/download PDF

9. 147P Genomic profile and response prediction of eribulin mesylate-based neoadjuvant chemotherapy in triple-negative breast cancer patients.

Author

Nishimura, T., Masuda, N., Kawaguchi, K., Takada, M., Maeshima, Y., Tanaka, S., Velaga, R., Kikawa, Y., Kadoya, T., Bando, H., Nakamura, R., Yamamoto, Y., Ueno, T., Yasojima, H., Ishiguro, H., Morita, S., Ohno, S., Haga, H., Ogawa, S., and Toi, M.

Subjects
*CANCER chemotherapy, *TRIPLE-negative breast cancer, *NEOADJUVANT chemotherapy, *CANCER patients, *ERIBULIN
Published
2021
Full Text
View/download PDF

10. 163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22).

Author

Bando, H., Masuda, N., Yamanaka, T., Kadoya, T., Takahashi, M., Nagai, S., Ohtani, S., Aruga, T., Suzuki, E., Kikawa, Y., Yasojima, H., Kasai, H., Ishiguro, H., Kawabata, H., Morita, S., Haga, H., Kataoka, T.R., Uozumi, R., Ohno, S., and Toi, M.

Subjects
*TRIPLE-negative breast cancer, *NEOADJUVANT chemotherapy, *CANCER patients
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results